Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease A Meta-Analysis of Randomized Controlled Trials

被引:119
作者
Chacko, Liza [1 ]
Howard, James P. [1 ]
Rajkumar, Christopher [1 ]
Nowbar, Alexandra N. [1 ]
Kane, Christopher [1 ]
Mahdi, Dina [1 ]
Foley, Michael [1 ]
Shun-Shin, Matthew [1 ]
Cole, Graham [1 ]
Sen, Sayan [1 ]
Al-Lamee, Rasha [1 ]
Francis, Darrel P. [1 ]
Ahmad, Yousif [1 ,2 ]
机构
[1] Imperial Coll London, London, England
[2] Columbia Univ, Med Ctr, New York, NY USA
来源
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES | 2020年 / 13卷 / 02期
基金
英国惠康基金;
关键词
acute coronary syndrome; coronary artery disease; fibrinolysis; myocardial infarction percutaneous coronary intervention; FRACTIONAL FLOW RESERVE; INTENSIVE MEDICAL THERAPY; CONSERVATIVE STRATEGIES; ELDERLY-PATIENTS; ONLY REVASCULARIZATION; PRIMARY ANGIOPLASTY; ANGINA-PECTORIS; CLINICAL-TRIAL; OPEN-LABEL; ISCHEMIA;
D O I
10.1161/CIRCOUTCOMES.119.006363
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In patients presenting with ST-segment-elevation myocardial infarction, percutaneous coronary intervention (PCI) reduces mortality when compared with fibrinolysis. In other forms of coronary artery disease (CAD), however, it has been controversial whether PCI reduces mortality. In this meta-analysis, we examine the benefits of PCI in (1) patients post-myocardial infarction (MI) who did not receive immediate revascularization; (2) patients who have undergone primary PCI for ST-segment-elevation myocardial infarction but have residual coronary lesions; (3) patients who have suffered a non-ST-segment-elevation acute coronary syndrome; and (4) patients with truly stable CAD with no recent infarct. This analysis includes data from the recently presented International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) and Complete versus Culprit-Only Revascularization Strategies to Treat Multivessel Disease after Early PCI for STEMI (COMPLETE) trials. Methods and Results: We systematically identified all randomized trials of PCI on a background of medical therapy for the treatment of CAD. The ISCHEMIA trial, presented in November 2019, was eligible for inclusion. Data were combined using a random-effects meta-analysis. The primary end point was all-cause mortality. Forty-six trials, including 37 757 patients, were eligible. In the 3 unstable scenarios, PCI had the following effects on mortality: unrevascularized post-MI relative risk (RR) 0.68 (95% CI, 0.45-1.03); P=0.07; multivessel disease following ST-segment-elevation myocardial infarction (RR, 0.84 [95% CI, 0.69-1.04]; P=0.11); non-ST-segment-elevation acute coronary syndrome (RR, 0.84 [95% CI, 0.72-0.97]; P=0.02). Overall, in these unstable scenarios PCI was associated with a significant reduction in mortality (RR, 0.84 [95% CI, 0.75-0.93]; P=0.02). In unstable CAD, PCI also reduced cardiac death (RR, 0.69 [95% CI, 0.53-0.90]; P=0.007) and MI (RR, 0.74 [95% CI, 0.62-0.90]; P=0.002). For stable CAD, PCI did not reduce mortality (RR, 0.98 [95% CI, 0.87-1.11]), cardiac death (RR, 0.89 [95% CI, 0.71-1.12]; P=0.33), or MI (RR, 0.96 [95% CI, 0.86-1.08]; P=0.54). Conclusions: PCI prevents death, cardiac death, and MI in patients with unstable CAD. For patients with stable CAD, PCI shows no evidence of an effect on any of these outcomes.
引用
收藏
页数:15
相关论文
共 57 条
  • [1] Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial
    Al-Lamee, Rasha
    Thompson, David
    Dehbi, Hakim-Moulay
    Sen, Sayan
    Tang, Kare
    Davies, John
    Keeble, Thomas
    Mielewczik, Michael
    Kaprielian, Raffi
    Malik, Iqbal S.
    Nijjer, Sukhjinder S.
    Petraco, Ricardo
    Cook, Christopher
    Ahmad, Yousif
    Howard, James
    Baker, Christopher
    Sharp, Andrew
    Gerber, Robert
    Talwar, Suneel
    Assomull, Ravi
    Mayet, Jamil
    Wensel, Roland
    Collier, David
    Shun-Shin, Matthew
    Thom, Simon A.
    Davies, Justin E.
    Francis, Darrel P.
    [J]. LANCET, 2018, 391 (10115) : 31 - 40
  • [2] Dobutamine Stress Echocardiography Ischemia as a Predictor of the Placebo-Controlled Efficacy of Percutaneous Coronary Intervention in Stable Coronary Artery Disease The Stress Echocardiography-Stratified Analysis of ORBITA
    Al-Lamee, Rasha K.
    Shun-Shin, Matthew J.
    Howard, James P.
    Nowbar, Alexandra N.
    Rajkumar, Christopher
    Thompson, David
    Sen, Sayan
    Nijjer, Sukhjinder
    Petraco, Ricardo
    Davies, John
    Keeble, Thomas
    Tang, Kare
    Malik, Iqbal
    Bual, Nina
    Cook, Christopher
    Ahmad, Yousif
    Seligman, Henry
    Sharp, Andrew S. P.
    Gerber, Robert
    Talwar, Suneel
    Assomull, Ravi
    Cole, Graham
    Keenan, Niall G.
    Kanaganayagam, Gajen
    Sehmi, Joban
    Wensel, Roland
    Harrell, Frank E., Jr.
    Mayet, Jamil
    Thom, Simon
    Davies, Justin E.
    Francis, Darrel P.
    [J]. CIRCULATION, 2019, 140 (24) : 1971 - 1980
  • [3] ONE-YEAR RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI) IIIB CLINICAL-TRIAL - A RANDOMIZED COMPARISON OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR VERSUS PLACEBO AND EARLY INVASIVE VERSUS EARLY CONSERVATIVE STRATEGIES IN UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL-INFARCTION
    ANDERSON, HV
    CANNON, CP
    STONE, PH
    WILLIAMS, DO
    MCCABE, CH
    KNATTERUD, GL
    THOMPSON, B
    WILLERSON, JT
    BRAUNWALD, E
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (07) : 1643 - 1650
  • [4] [Anonymous], 2011, COCHR HDB SYST REV I
  • [5] Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis - A randomized trial
    Bech, GJW
    De Bruyne, S
    Pijls, NHJ
    de Muinck, ED
    Hoorntje, JC
    Escaned, J
    Stella, PR
    Boersma, E
    Bartunek, J
    Koolen, JJ
    Wijns, W
    [J]. CIRCULATION, 2001, 103 (24) : 2928 - 2934
  • [6] Bertram P, 1999, N ENGL J MED, V7
  • [7] Optimal medical therapy with or without PCI for stable coronary disease
    Boden, William E.
    O'Rourke, Robert A.
    Teo, Koon K.
    Hartigan, Pamela M.
    Maron, David J.
    Kostuk, William J.
    Knudtson, Merril
    Dada, Marcin
    Casperson, Paul
    Harris, Crystal L.
    Chaitman, Bernard R.
    Shaw, Leslee
    Gosselin, Gilbert
    Nawaz, Shah
    Title, Lawrence M.
    Gau, Gerald
    Blaustein, Alvin S.
    Booth, David C.
    Bates, Eric R.
    Spertus, John A.
    Berman, Daniel S.
    Mancini, G. B. John
    Weintraub, William S.
    Boden, W.
    O'Rourke, R.
    Teo, K.
    Hartigan, P.
    Weintraub, W.
    Maron, D.
    Mancini, J.
    Weintraub, W.
    Boden, W.
    O'Rourke, R.
    Teo, K.
    Hartigan, P.
    Knudtson, M.
    Maron, D.
    Bates, E.
    Blaustein, A.
    Booth, D.
    Carere, R.
    Ellis, S.
    Gosselin, G.
    Gau, G.
    Jacobs, A.
    King, S., III
    Kostuk, W.
    Harris, C.
    Spertus, J.
    Peduzzi, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) : 1503 - 1516
  • [8] Bogaty P, 2020, NEW ENGL J MED, V382, P1568, DOI [10.1056/NEJMoa1907775, 10.1056/NEJMc2000278]
  • [9] Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
    Cannon, CP
    Weintraub, WS
    Demopoulos, LA
    Vicari, R
    Frey, MJ
    Lakkis, N
    Neumann, FJ
    Robertson, DH
    DeLucca, PT
    DiBattiste, PM
    Gibson, CM
    Braunwald, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) : 1879 - 1887
  • [10] Chamberlain DA, 1997, LANCET, V350, P461